This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Viladrich, P F
Right arrow Articles by Ariza, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Viladrich, P F
Right arrow Articles by Ariza, J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 December; 35(12): 2467-2472

Evaluation of vancomycin for therapy of adult pneumococcal meningitis.

P F Viladrich, F Gudiol, J Liñares, R Pallarés, I Sabaté, G Rufí and J Ariza

Infectious Disease, Hospital de Bellvitge, University of Barcelona, Spain.

ABSTRACT

The emergence of pneumococci resistant to penicillin and other agents prompted us to evaluate intravenous vancomycin for the therapy of pneumococcal meningitis, which has an overall mortality of 30%. Eleven consecutive adult patients with cerebrospinal fluid (CSF)-culture-proven pneumococcal meningitis and positive initial CSF Gram stain were given intravenous vancomycin (usual dosage, 7.5 mg/kg every 6 h for 10 days). The MBCs of vancomycin ranged from 0.25 to 0.5 micrograms/ml. Early adjunctive therapy with intravenous dexamethasone, mannitol, and sodium phenytoin was also instituted. After 48 h of therapy, all 11 patients showed a satisfactory clinical response, although the CSF culture remained positive in one case; median trough CSF and serum vancomycin levels were 2 and 5.1 micrograms/ml, respectively, and trough CSF bactericidal titers ranged from less than 1:2 to 1:16. On day 3, one patient died of acute heart failure. Four patients had clinical failure at on days 4 (two patients), 7 (one), and 8 (one) of therapy; they all immediately responded to a change in antibiotic therapy. The remaining six patients were cured after 10 days of vancomycin therapy. At this point, median peak CSF and serum vancomycin levels were 1.9 and 18.5 micrograms/ml, respectively. A transient alteration of renal function occurred in two patients, and persistent slight hypoacusia occurred in three patients. In summary, 11 adults with pneumococcal meningitis were treated with vancomycin and early adjunctive therapy including dexamethasone. All patients initially improved, and 10 were ultimately cured of the infection. However, four patients experienced a therapeutic failure, which led to a change in vancomycin therapy.

Antimicrob Agents Chemother. 1991 December; 35(12): 2467-2472




This article has been cited by other articles:

  • Sung, H., Shin, H. B., Kim, M.-N., Lee, K., Kim, E.-C., Song, W., Jeong, S. H., Lee, W.-G., Park, Y.-J., Eliopoulos, G. M. (2006). Vancomycin-Tolerant Streptococcus pneumoniae in Korea. J. Clin. Microbiol. 44: 3524-3528 [Abstract] [Full Text]  
  • van de Beek, D., de Gans, J., Tunkel, A. R., Wijdicks, E. F.M. (2006). Community-Acquired Bacterial Meningitis in Adults. NEJM 354: 44-53 [Full Text]  
  • Lewin, J. J. III, Lapointe, M., Ziai, W. C. (2005). Central Nervous System Infections in the Critically Ill. Journal of Pharmacy Practice 18: 25-41 [Abstract]  
  • Fernandez, A., Cabellos, C., Tubau, F., Maiques, J. M., Domenech, A., Ribes, S., Linares, J., Viladrich, P. F., Gudiol, F. (2005). Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 55: 78-83 [Abstract] [Full Text]  
  • El Bashir, H, Laundy, M, Booy, R (2003). Diagnosis and treatment of bacterial meningitis. Arch. Dis. Child. 88: 615-620 [Abstract] [Full Text]  
  • Cabellos, C., Fernandez, A., Maiques, J. M., Tubau, F., Ardanuy, C., Viladrich, P. F., Linares, J., Gudiol, F. (2003). Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother. 47: 1907-1911 [Abstract] [Full Text]  
  • Shafran, S. D (2003). Dexamethasone improved disability in acute bacterial meningitis. Evid. Based Med. 8: 86-86 [Full Text]  
  • de Gans, J., van de Beek, D., the European Dexamethasone in Adulthood Bacterial, (2002). Dexamethasone in Adults with Bacterial Meningitis. NEJM 347: 1549-1556 [Abstract] [Full Text]  
  • Lanska, D. J. (2002). Anthrax meningoencephalitis. Neurology 59: 327-334 [Abstract] [Full Text]  
  • Martinez-Lacasa, J., Cabellos, C., Martos, A., Fernandez, A., Tubau, F., Viladrich, P. F., Linares, J., Gudiol, F. (2002). Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 49: 507-513 [Abstract] [Full Text]  
  • Gerber, J., Smirnov, A., Wellmer, A., Ragheb, J., Prange, J., Schutz, E., Wettich, K., Kalich, S., Nau, R. (2001). Activity of LY333328 in Experimental Meningitis Caused by a Streptococcus pneumoniae Strain Susceptible to Penicillin. Antimicrob. Agents Chemother. 45: 2169-2172 [Abstract] [Full Text]  
  • Cottagnoud, P., Gerber, C. M., Acosta, F., Cottagnoud, M., Neftel, K., Tauber, M. G. (2000). Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 46: 981-985 [Abstract] [Full Text]  
  • Asahi, Y., Takeuchi, Y., Ubukata, K. (1999). Diversity of Substitutions within or Adjacent to Conserved Amino Acid Motifs of Penicillin-Binding Protein 2X in Cephalosporin-Resistant Streptococcus pneumoniae Isolates. Antimicrob. Agents Chemother. 43: 1252-1255 [Abstract] [Full Text]  
  • Ahmed, A., Jafri, H., Lutsar, I., McCoig, C. C., Trujillo, M., Wubbel, L., Shelton, S., McCracken, G. H. Jr. (1999). Pharmacodynamics of Vancomycin for the Treatment of Experimental Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother. 43: 876-881 [Abstract] [Full Text]  
  • Arditi, M., Mason Jr, E. O., Bradley, J. S., Tan, T. Q., Barson, W. J., Schutze, G. E., Wald, E. R., Givner, L. B., Kim, K. S., Yogev, R., Kaplan, S. L. (1998). Three-Year Multicenter Surveillance of Pneumococcal Meningitis in Children: Clinical Characteristics, and Outcome Related to Penicillin Susceptibility and Dexamethasone Use. Pediatrics 102: 1087-1097 [Abstract] [Full Text]  
  • Kaplan, S. L., Mason, E. O. Jr. (1998). Management of Infections Due to Antibiotic-Resistant Streptococcus pneumoniae. Clin. Microbiol. Rev. 11: 628-644 [Abstract] [Full Text]  
  • Quagliarello, V. J., Scheld, W. M. (1997). Treatment of Bacterial Meningitis. NEJM 336: 708-716 [Full Text]  
  • Committee on Infectious Diseases, (1997). Therapy for Children With Invasive Pneumococcal Infections. Pediatrics 99: 289-299 [Abstract] [Full Text]  
  • Redondo, E., Clynes, N., Hofmann, J., Cetron, M. S., Breiman, R. F., Farley, M. M., Pallares, R., Linares, J., Gudiol, F. (1996). Drug-Resistant Streptococcus pneumoniae. NEJM 334: 53-55 [Full Text]  
  • Hofmann, J., Cetron, M. S., Farley, M. M., Baughman, W. S., Facklam, R. R., Elliott, J. A., Deaver, K. A., Breiman, R. F. (1995). The Prevalence of Drug-Resistant Streptococcus pneumoniae In Atlanta. NEJM 333: 481-486 [Abstract] [Full Text]  
  • CHESNEY, P. J. (1992). The Escalating Problem of Antimicrobial Resistance in Streptococcus pneumoniae. Arch Pediatr Adolesc Med 146: 912-916 [Abstract]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»